A 32-year-old woman presents to the clinic with several months of fatigue, intermittent right upper quadrant discomfort, and joint pain. Her medical history is significant for autoimmune thyroid disease. She takes levothyroxine daily. She does not drink alcohol. Temperature is 36.8°C (98.2°F), blood pressure is 118/74 mm Hg, pulse is 78/min, and respiratory rate is 14/min. Physical examination is notable only for mild hepatomegaly. Laboratory studies reveal the following:
Additional testing demonstrates elevated serum IgG levels and positive anti-smooth muscle antibodies. Which of the following is the most appropriate initial treatment?
The correct answer is:
B) Prednisone
This patient has autoimmune hepatitis, an immune-mediated inflammatory liver disease characterized by elevated aminotransferases, hypergammaglobulinemia (especially elevated IgG), and characteristic autoantibodies. The association with another autoimmune disorder is an important clue. The hepatocellular pattern of injury (marked AST and ALT elevation) helps distinguish autoimmune hepatitis from cholestatic disorders such as primary biliary cholangitis.
Autoimmune hepatitis can progress to cirrhosis if untreated. Initial treatment typically involves corticosteroid therapy, often with prednisone, followed by long-term immunosuppressive strategies in selected patients. Board-style questions frequently distinguish autoimmune hepatitis from primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) by emphasizing the laboratory pattern, associated antibodies, and patient demographics.
Answer choice A: Ciprofloxacin, is incorrect.
Antibiotics are not used to treat autoimmune hepatitis. Ciprofloxacin may be used for selected infections but does not address immune-mediated hepatic inflammation.
Answer choice C: Therapeutic phlebotomy, is incorrect.
Phlebotomy is indicated for hereditary hemochromatosis and would not improve autoimmune liver injury.
Answer choice D: Ursodeoxycholic acid, is incorrect.
This is a tempting distractor because it is used in autoimmune-associated liver disease. However, ursodeoxycholic acid is first-line treatment for primary biliary cholangitis, not autoimmune hepatitis.
Answer choice E: Weight loss alone, is incorrect.
Weight loss is appropriate for metabolic dysfunction-associated steatohepatitis (MASH) but would not adequately treat active autoimmune hepatitis.
Key Learning Point
Autoimmune hepatitis presents with elevated aminotransferases, elevated IgG levels, and characteristic autoantibodies and is typically treated initially with corticosteroids.
